{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:10:33Z","timestamp":1761808233780,"version":"3.37.3"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1136\/annrheumdis-2018-214747","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T22:15:29Z","timestamp":1544048129000},"page":"e22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Paradoxical pulmonary event under tocilizumab treatment for systemic sclerosis-associated usual interstitial pneumonia"],"prefix":"10.1016","volume":"79","author":[{"given":"Ana Luisa","family":"Oliveira","sequence":"first","affiliation":[]},{"given":"Carina","family":"Ruano","sequence":"additional","affiliation":[]},{"given":"Nuno","family":"Riso","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9","family":"Cepeda Ribeiro","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8917-6592","authenticated-orcid":false,"given":"Maria Francisca","family":"Moraes-Fontes","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2018-214747_bib1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2018-214747_bib2","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.2106012","article-title":"Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome","volume":"165","author":"Bouros","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1136\/annrheumdis-2018-214747_bib3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/rheumatology\/keu435","article-title":"Treatment of systemic sclerosis with tocilizumab","volume":"54","author":"Fernandes das Neves","year":"2015","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2018-214747_bib4","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","article-title":"Acute exacerbations of idiopathic pulmonary fibrosis","volume":"176","author":"Collard","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1136\/annrheumdis-2018-214747_bib5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases","volume":"41","author":"Perez-Alvarez","year":"2011","journal-title":"Semin Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724015280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724015280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2018-214747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T06:51:41Z","timestamp":1736059901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724015280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0003496724015280"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2018-214747","relation":{},"ISSN":["0003-4967"],"issn-type":[{"type":"print","value":"0003-4967"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paradoxical pulmonary event under tocilizumab treatment for systemic sclerosis-associated usual interstitial pneumonia","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2018-214747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 \u00a9 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}